Sodium Tungstate in Obesity

Hospital Clinic of Barcelona44 enrolled

Overview

The purpose of this study is to compare the efficacy and safety of sodium tungstate versus placebo in patients with obesity (grade I and II).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Obesity

Interventions

Sodium TungstateDRUG

Sodium Tungstate, 200 mg BID, oral route during 6 weeks

PlaceboDRUG

Placebo, BID, oral route during 6 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * BMI: 30-39.9 Kg/m2 * In case of male gender, 18 to 65 years old * In case of female gender, diagnosis of menopause * Body weight changes \< 3 kg in the last 3 months * In case of arterial hypertension or dyslipemia, no changes in dose in the last 2 months Exclusion criteria: * In case of female gender, absence of menopause * Evidence of secondary causes of obesity * Diabetes, type II * Concomitant treatment with drugs affecting body weight * Previous surgical intervention of obesity

Locations (1)

Hospiral Clinic de Barcelona

Barcelona, Barcelona, Spain

Outcomes

Primary Outcomes

weight loss

Time frame: six weeks

Secondary Outcomes

changes in lipids

Time frame: 6 weeks

changes in caloric intake and in hungry sensation

Time frame: 6 weeks

resting metabolic rate

Time frame: 6 weeks

changes in body composition

Time frame: 6 weeks

adverse events

Time frame: 6 weeks

changes in hormonal parameters

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.